Related references
Note: Only part of the references are listed.Remarkable elevation of fibrinolysis markers and procalcitonin associated with dabrafenib plus trametinib combination therapy: Uncommon adverse events
Yoshiyuki Nakamura et al.
JOURNAL OF DERMATOLOGY (2020)
Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicine
Jesus Vera et al.
SUPPORTIVE CARE IN CANCER (2019)
Dabrafenib and trametinib treatment-associated fevers in metastatic melanoma causing extreme elevation in procalcitonin in the absence of infection
Timothy D. Clay et al.
ANTI-CANCER DRUGS (2018)
Diagnostic Value of Procalcitonin in Predicting Bacteremia in Intensive Care Unit
Tuna Demirdal et al.
INDIAN JOURNAL OF CRITICAL CARE MEDICINE (2018)
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G. V. Long et al.
ANNALS OF ONCOLOGY (2017)
Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists
Victoria Atkinson et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2016)
Procalcitonin as diagnostic marker of infection in solid tumors patients with fever
B. Vincenzi et al.
SCIENTIFIC REPORTS (2016)
The pathophysiological basis and consequences of fever
Edward James Walter et al.
CRITICAL CARE (2016)
Clinical Value of Procalcitonin for Patients With Suspected Bloodstream Infection
Takuya Hattori et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2014)
The Utility of Proadrenomedullin and Procalcitonin in Comparison to C-Reactive Protein as Predictors of Sepsis and Bloodstream Infections in Critically III Patients With Cancer
Labib Debiane et al.
CRITICAL CARE MEDICINE (2014)
Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro
MWN Nijsten et al.
CRITICAL CARE MEDICINE (2000)